IMDX - Insight Molecular Diagnostics Inc. News

Discover

IMDX

Insight Molecular Diagnostics Inc.

5.06

1 x 5.05

1 x 5.09

bid

ask

0.06

1.20%

11:59 AM

timesize

Ytd	-32.53%
1y	78.17%

4.92

day range

5.20

2.33

52 week range

8.51

Open	5.00	Prev Close	5.00	Low	4.92	High	5.20	Mkt Cap	134.21M
Vol	23.11K	Avg Vol	334.76K	EPS	-1.19	P/E	-4.20	Forward P/E	N/A
Beta	1.76	Short Ratio	N/A	Inst. Own	N/A	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-10	50-d Avg	5.54	200-d Avg	5.44	1yr Est	0.00

IMDX News

globenewswire.com

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfoli

NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMD

globenewswire.com

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and t

globenewswire.com

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Eco

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidn

globenewswire.com

Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Che

NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMD

globenewswire.com

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journa

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to ei

seekingalpha.com

Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcript

globenewswire.com

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American T

NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMD

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

seekingalpha.com

Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript

globenewswire.com

IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization

Progressing toward commercialization with third-party head-to-head data publications and GALACTIC re

benzinga.com

Earnings Scheduled For May 13, 2026

benzinga.com

Alpha Buying: Insider Conviction in High-Risk Biotech

globenewswire.com

Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay

Positive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Im

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

seekingalpha.com

Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call Transcript

globenewswire.com

IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasd

benzinga.com

Earnings Scheduled For March 26, 2026

globenewswire.com

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare

NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IM

globenewswire.com

Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model

NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMD

defenseworld.net

Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review

Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a

defenseworld.net

Head-To-Head Contrast: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)

Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a

defenseworld.net

Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)

Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a

defenseworld.net

Financial Comparison: Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX)

Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a

defenseworld.net

Analyzing Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX)

Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a

benzinga.com

12 Health Care Stocks Moving In Tuesday's Intraday Session

benzinga.com

Earnings Scheduled For November 10, 2025

benzinga.com

Earnings Scheduled For August 11, 2025